Exercise or conversion by Greg Pyszczymuka of 209 shares of Aytu BioScience subject to Rule 16b-3
| AYTU Stock | USD 1.30 0.05 3.70% |
Slightly above 61% of Aytu BioScience's investor base is looking to short. The analysis of overall sentiment of trading Aytu BioScience stock suggests that many investors are alarmed at this time. Aytu BioScience's investing sentiment can be driven by a variety of factors including economic data, Aytu BioScience's earnings reports, geopolitical events, and overall market trends.
Aytu |
Filed transaction by Aytu Biopharma Inc officer. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
Read at macroaxis.com
Aytu BioScience Fundamental Analysis
We analyze Aytu BioScience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aytu BioScience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aytu BioScience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Aytu BioScience is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Aytu BioScience Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aytu BioScience stock to make a market-neutral strategy. Peer analysis of Aytu BioScience could also be used in its relative valuation, which is a method of valuing Aytu BioScience by comparing valuation metrics with similar companies.
Peers
Aytu BioScience Related Equities
| SGIOY | Shionogi | 3.75 | ||||
| LFCR | Lifecore Biomedical | 2.86 | ||||
| SNOA | Sonoma Pharmaceuticals | 0.83 | ||||
| IRWD | Ironwood Pharmaceuticals | 1.10 | ||||
| DERM | Journey Medical | 1.49 | ||||
| SHPH | Shuttle Pharmaceuticals | 1.64 | ||||
| AVDL | Avadel Pharmaceuticals | 1.70 | ||||
| SBFM | Sunshine Biopharma | 2.04 | ||||
| EVOK | Evoke Pharma | 4.54 | ||||
| ESPR | Esperion Therapeutics | 4.95 | ||||
| AQST | Aquestive Therapeutics | 5.41 | ||||
| FLGC | Flora Growth | 5.56 | ||||
| PTPI | Petros Pharmaceuticals | 8.33 | ||||
| SXTC | China SXT | 25.45 |
Additional Tools for Aytu Stock Analysis
When running Aytu BioScience's price analysis, check to measure Aytu BioScience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aytu BioScience is operating at the current time. Most of Aytu BioScience's value examination focuses on studying past and present price action to predict the probability of Aytu BioScience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aytu BioScience's price. Additionally, you may evaluate how the addition of Aytu BioScience to your portfolios can decrease your overall portfolio volatility.